Pub Date : 2026-02-01Epub Date: 2025-12-03DOI: 10.1002/nau.70203
Joshua A Cohn, Brian J Linder
{"title":"Urodynamics in Focus: Applications, Controversies, and Evolving Practices.","authors":"Joshua A Cohn, Brian J Linder","doi":"10.1002/nau.70203","DOIUrl":"10.1002/nau.70203","url":null,"abstract":"","PeriodicalId":19200,"journal":{"name":"Neurourology and Urodynamics","volume":" ","pages":"253"},"PeriodicalIF":1.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145669293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2025-10-09DOI: 10.1002/nau.70157
Dora Jericevic Schwartz, Suditi Rahematpura, Benjamin Brucker
Introduction: This review examines the role of urodynamics (UDS) in evaluating lower urinary tract symptoms (LUTS) following radical prostatectomy. We first present typical urodynamic findings in post-prostatectomy men, then discuss applications of UDS, and finally examine treatment pathways for post-prostatectomy LUTS beyond stress urinary incontinence (SUI) surgery.
Methods: A narrative review was performed focusing on the current primary literature and society guidelines on the role of UDS post-prostatectomy.
Results: LUTS after prostatectomy are common, most frequently storage LUTS, specifically SUI. For the index patient with clinically suspected SUI after prostate treatment, routine UDS before SUI surgery have not been shown to impact postsurgical continence outcomes. In cases where there is diagnostic uncertainty following noninvasive lower urinary tract evaluation, UDS plays an important role. UDS are highly beneficial in complex scenarios, such as severe mixed LUTS, prior radiation therapy, impaired bladder compliance, detrusor underactivity, and/or previous SUI surgery. Fluoroscopy during UDS and cystoscopy can provide additional clarity and confirmation of the diagnosis suggested by UDS.
Conclusion: UDS are useful adjuncts in appropriately selected post-prostatectomy patients with LUTS, typically with complicating factors.
{"title":"The Role of Urodynamics in Assessing Lower Urinary Tract Symptoms Post-Radical Prostatectomy: A Review.","authors":"Dora Jericevic Schwartz, Suditi Rahematpura, Benjamin Brucker","doi":"10.1002/nau.70157","DOIUrl":"10.1002/nau.70157","url":null,"abstract":"<p><strong>Introduction: </strong>This review examines the role of urodynamics (UDS) in evaluating lower urinary tract symptoms (LUTS) following radical prostatectomy. We first present typical urodynamic findings in post-prostatectomy men, then discuss applications of UDS, and finally examine treatment pathways for post-prostatectomy LUTS beyond stress urinary incontinence (SUI) surgery.</p><p><strong>Methods: </strong>A narrative review was performed focusing on the current primary literature and society guidelines on the role of UDS post-prostatectomy.</p><p><strong>Results: </strong>LUTS after prostatectomy are common, most frequently storage LUTS, specifically SUI. For the index patient with clinically suspected SUI after prostate treatment, routine UDS before SUI surgery have not been shown to impact postsurgical continence outcomes. In cases where there is diagnostic uncertainty following noninvasive lower urinary tract evaluation, UDS plays an important role. UDS are highly beneficial in complex scenarios, such as severe mixed LUTS, prior radiation therapy, impaired bladder compliance, detrusor underactivity, and/or previous SUI surgery. Fluoroscopy during UDS and cystoscopy can provide additional clarity and confirmation of the diagnosis suggested by UDS.</p><p><strong>Conclusion: </strong>UDS are useful adjuncts in appropriately selected post-prostatectomy patients with LUTS, typically with complicating factors.</p>","PeriodicalId":19200,"journal":{"name":"Neurourology and Urodynamics","volume":" ","pages":"270-278"},"PeriodicalIF":1.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145258592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
<p><strong>Background: </strong>Lower urinary tract (LUT) dysfunctions affect millions of patients globally. LUT dysfunctions are extremely common in patients with neurological diseases. Worldwide, subtype A of Botulinum Toxin A (BTXA) is regularly used to treat these disorders.</p><p><strong>Introduction: </strong>LUT dysfunctions have various patterns of expression. The most prevalent of these is neurogenic detrusor overactivity (NDO), which is strongly associated with neurological diseases and can significantly impact a patient's life.</p><p><strong>Objective: </strong>Onabotulinumtoxin A is a widely used drug for the treatment of neurogenic bladder. The purpose of this study is to evaluate its efficacy and safety across different dosages in patients with the condition.</p><p><strong>Data sources: </strong>Pubmed, Scopus, Web of Science.</p><p><strong>Review methods: </strong>Systematic literature review was performed to identify randomized, double-blind, placebo-controlled trials of onabotulinumtoxin A for NDO. Seven randomized controlled trials were incorporated in this meta-analysis. The primary outcome concerned urodynamic parameters, including Maximum Cystometric Capacity (MCC) and Maximum Detrusor Pressure (MDP); the mean number of Urinary Incontinence (UI) episodes per week was also assessed. Safety was evaluated by the incidence of various Adverse Events (AE). Data was extracted by two authors and statistical analysis was carried out using the Statistical Package for the Social Sciences (SPSS v.29).</p><p><strong>Results: </strong>Seven RCTs involving 1592 patients in total were included in the study, following screening of 1602 potentially relevant articles. The Onabotulinumtoxin A-treated groups showed a significant increase in MCC (Mean Difference ([MD]: 128.866, 95% Confidence Interval [CI]: 98.836, 158.896, p < 0.001, in the group that received 200 Units of Onabotulinumtoxin A; MD: 151.389, CI: 106.006, 196.773, p < 0.005, in the group that received 300Units of Onabotulinumtoxin A). There was also a significant decrease in MDP in the Onabotulinumtoxin A-treated groups (MD: -29.051, CI: -39.557, -18.545, p < 0.002, 200 U group; MD: -31.751, CI: -45.226, -18.276, p < 0.01, 300 U group). Additionally, no effect was noticed in the mean number of UI episodes per week (MD: -10.69, 95% CI: -33.86, 12.49, p = 0.11; MD: -10.55, 95% CI: -59.06, 37.97, p = 0.22, 200 U and 300 U respectively). Taking AEs into consideration, Onabotulinumtoxin A-treated groups were often associated with more complications, including urinary tract infections (UTI) (LogOR: 0.341, CI: 0.011, 0.67, p = 0.045, 200 U group; LogOR: 0.424, CI: 0.075, 0.773, p = 0.028, 300 U group) and urinary retention (UR) (LogOR: 1.746, CI: 0.869, 2.623, p = 0.008, 200 U group; LogOR: 1.879, CI: 0.679, 3.078, p = 0.021, 300 U group).</p><p><strong>Conclusions: </strong>Our meta-analyses found that Onabotulinumtoxin A can be beneficial in improving the urodynamic parameters (MCC and M
背景:下尿路(LUT)功能障碍影响着全球数百万患者。LUT功能障碍在神经系统疾病患者中极为常见。在世界范围内,A型肉毒毒素A (BTXA)经常用于治疗这些疾病。LUT功能障碍具有多种表达模式。其中最常见的是神经源性逼尿肌过度活动(NDO),这与神经系统疾病密切相关,并可能严重影响患者的生活。目的:肉毒杆菌毒素A是一种广泛应用于治疗神经源性膀胱的药物。本研究的目的是评估其在不同剂量下对患者的疗效和安全性。数据来源:Pubmed, Scopus, Web of Science。综述方法:采用系统的文献综述来确定肉毒杆菌毒素A治疗NDO的随机、双盲、安慰剂对照试验。本荟萃分析纳入了7项随机对照试验。主要结局涉及尿动力学参数,包括最大膀胱容量(MCC)和最大逼尿肌压力(MDP);每周尿失禁(UI)发作的平均次数也被评估。通过各种不良事件(AE)的发生率来评估安全性。数据由两位作者提取,并使用社会科学统计软件包(SPSS v.29)进行统计分析。结果:在筛选了1602篇可能相关的文章后,共纳入了7项随机对照试验,共涉及1592例患者。单肉毒杆菌毒素a治疗组MCC显著升高(平均差值[MD]: 128.866, 95%可信区间[CI]: 98.836, 158.896, p)。结论:我们的荟萃分析发现单肉毒杆菌毒素a可改善尿动力学参数(MCC和MDP)。就安全性而言,药物治疗组发生尿路感染或尿路感染的可能性略高。
{"title":"Comparative Effectiveness of Botulinum Toxin a Versus Placebo for Neurogenic Overactive Bladder: A Meta-Analysis.","authors":"Konstantinos Tassoudis, Zachos Ioannis, Dimitropoulos Konstatninos, Evmorfopoulos Konstantinos, Marsitopoulos Konstantinos, Vassilios Tassoudis, Vassilios Tzortzis","doi":"10.1002/nau.70211","DOIUrl":"10.1002/nau.70211","url":null,"abstract":"<p><strong>Background: </strong>Lower urinary tract (LUT) dysfunctions affect millions of patients globally. LUT dysfunctions are extremely common in patients with neurological diseases. Worldwide, subtype A of Botulinum Toxin A (BTXA) is regularly used to treat these disorders.</p><p><strong>Introduction: </strong>LUT dysfunctions have various patterns of expression. The most prevalent of these is neurogenic detrusor overactivity (NDO), which is strongly associated with neurological diseases and can significantly impact a patient's life.</p><p><strong>Objective: </strong>Onabotulinumtoxin A is a widely used drug for the treatment of neurogenic bladder. The purpose of this study is to evaluate its efficacy and safety across different dosages in patients with the condition.</p><p><strong>Data sources: </strong>Pubmed, Scopus, Web of Science.</p><p><strong>Review methods: </strong>Systematic literature review was performed to identify randomized, double-blind, placebo-controlled trials of onabotulinumtoxin A for NDO. Seven randomized controlled trials were incorporated in this meta-analysis. The primary outcome concerned urodynamic parameters, including Maximum Cystometric Capacity (MCC) and Maximum Detrusor Pressure (MDP); the mean number of Urinary Incontinence (UI) episodes per week was also assessed. Safety was evaluated by the incidence of various Adverse Events (AE). Data was extracted by two authors and statistical analysis was carried out using the Statistical Package for the Social Sciences (SPSS v.29).</p><p><strong>Results: </strong>Seven RCTs involving 1592 patients in total were included in the study, following screening of 1602 potentially relevant articles. The Onabotulinumtoxin A-treated groups showed a significant increase in MCC (Mean Difference ([MD]: 128.866, 95% Confidence Interval [CI]: 98.836, 158.896, p < 0.001, in the group that received 200 Units of Onabotulinumtoxin A; MD: 151.389, CI: 106.006, 196.773, p < 0.005, in the group that received 300Units of Onabotulinumtoxin A). There was also a significant decrease in MDP in the Onabotulinumtoxin A-treated groups (MD: -29.051, CI: -39.557, -18.545, p < 0.002, 200 U group; MD: -31.751, CI: -45.226, -18.276, p < 0.01, 300 U group). Additionally, no effect was noticed in the mean number of UI episodes per week (MD: -10.69, 95% CI: -33.86, 12.49, p = 0.11; MD: -10.55, 95% CI: -59.06, 37.97, p = 0.22, 200 U and 300 U respectively). Taking AEs into consideration, Onabotulinumtoxin A-treated groups were often associated with more complications, including urinary tract infections (UTI) (LogOR: 0.341, CI: 0.011, 0.67, p = 0.045, 200 U group; LogOR: 0.424, CI: 0.075, 0.773, p = 0.028, 300 U group) and urinary retention (UR) (LogOR: 1.746, CI: 0.869, 2.623, p = 0.008, 200 U group; LogOR: 1.879, CI: 0.679, 3.078, p = 0.021, 300 U group).</p><p><strong>Conclusions: </strong>Our meta-analyses found that Onabotulinumtoxin A can be beneficial in improving the urodynamic parameters (MCC and M","PeriodicalId":19200,"journal":{"name":"Neurourology and Urodynamics","volume":" ","pages":"335-352"},"PeriodicalIF":1.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145966316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2025-11-29DOI: 10.1002/nau.70190
Sean Lim, Zein Alhamdani, Kirby R Qin, Alexander Nesbitt, Paul Manohar, Matthew Harper, Scott Donnellan, Janelle Brennan, Weranja Ranasinghe
<p><strong>Introduction: </strong>Interstitial cystitis (IC) is a chronic pelvic condition in the absence of other pathology leading to significant morbidity with limited available treatment options. Cystoscopic hydrodistension (HD) remains an offered intervention for diagnosis and management, providing temporary relief in some patients. There is no overall consensus regarding the optimal duration of HD. This systematic review aims to comprehensively assess the existing literature to identify if there is a relationship between HD time and treatment efficacy.</p><p><strong>Materials and methods: </strong>A systematic search in MEDLINE, Embase, and PubMed between January 1969 to April 2024 was performed to identify relevant articles investigating the efficacy of HD as a sole treatment for IC. Two independent reviewers screened abstracts and full texts, and a third resolved conflicts. Quality assessment was performed by two independent blinded authors using The Risk Of Bias In Non-randomized Studies - of Interventions (ROBINS-I) assessment tool. Data regarding population characteristics, duration of HD, treatment number and method, outcome measurements and values were extracted. Included articles were subcategorized into standard (< 15 min) and prolonged (> 15 min) HD durations.</p><p><strong>Results: </strong>A total of 1404 patients in 14 studies were included. Ten studies were prospective or retrospective cohort studies, and four were randomized controlled trials. Nine trials investigated the effect of HD for 15 min or less. Of these, four demonstrated no statistically significant differences in preoperative and post operative symptoms and voiding function between 1 month and 6 months. Four trials found significant improvement in subjective patient symptom scores. Of these, one study investigated two groups of different HD times via different surgeons, and found significant improvements in pain scores for patients in those undergoing HD for 2 min (Pre: 2.4 vs. Post: 5.5) and over 5 min (Pre: 1.3 vs. Post: 3.6). A final study found a time to therapeutic failure post 3 min HD of 25.2 months. Five trials performed prolonged HD between 30 min to 2 h in a total of 152 patients. All were older studies (1977-2003) and performed HD under spinal or local anesthetic. These studies demonstrated long term symptomatic improvement in included participants (32.3%-67.3%) with follow up durations of 7 months to 3.2 years. Overall risk of bias across domains was assessed as high between included studies.</p><p><strong>Conclusions: </strong>HD remains a contentious treatment option for IC, with limited long-term results in the literature. Our study suggests longer HD times may result in improved efficacy and duration of symptom relief but in the setting of potentially increased risks of severe complications including bladder perforation. Risk of bias, observational study designs, heterogeneity, and lack direct comparisons in durations of HD limits our conclusions.
{"title":"Optimal Duration of Hydrodistension for Symptomatic Treatment of Interstitial Cystitis: A Systematic Review.","authors":"Sean Lim, Zein Alhamdani, Kirby R Qin, Alexander Nesbitt, Paul Manohar, Matthew Harper, Scott Donnellan, Janelle Brennan, Weranja Ranasinghe","doi":"10.1002/nau.70190","DOIUrl":"10.1002/nau.70190","url":null,"abstract":"<p><strong>Introduction: </strong>Interstitial cystitis (IC) is a chronic pelvic condition in the absence of other pathology leading to significant morbidity with limited available treatment options. Cystoscopic hydrodistension (HD) remains an offered intervention for diagnosis and management, providing temporary relief in some patients. There is no overall consensus regarding the optimal duration of HD. This systematic review aims to comprehensively assess the existing literature to identify if there is a relationship between HD time and treatment efficacy.</p><p><strong>Materials and methods: </strong>A systematic search in MEDLINE, Embase, and PubMed between January 1969 to April 2024 was performed to identify relevant articles investigating the efficacy of HD as a sole treatment for IC. Two independent reviewers screened abstracts and full texts, and a third resolved conflicts. Quality assessment was performed by two independent blinded authors using The Risk Of Bias In Non-randomized Studies - of Interventions (ROBINS-I) assessment tool. Data regarding population characteristics, duration of HD, treatment number and method, outcome measurements and values were extracted. Included articles were subcategorized into standard (< 15 min) and prolonged (> 15 min) HD durations.</p><p><strong>Results: </strong>A total of 1404 patients in 14 studies were included. Ten studies were prospective or retrospective cohort studies, and four were randomized controlled trials. Nine trials investigated the effect of HD for 15 min or less. Of these, four demonstrated no statistically significant differences in preoperative and post operative symptoms and voiding function between 1 month and 6 months. Four trials found significant improvement in subjective patient symptom scores. Of these, one study investigated two groups of different HD times via different surgeons, and found significant improvements in pain scores for patients in those undergoing HD for 2 min (Pre: 2.4 vs. Post: 5.5) and over 5 min (Pre: 1.3 vs. Post: 3.6). A final study found a time to therapeutic failure post 3 min HD of 25.2 months. Five trials performed prolonged HD between 30 min to 2 h in a total of 152 patients. All were older studies (1977-2003) and performed HD under spinal or local anesthetic. These studies demonstrated long term symptomatic improvement in included participants (32.3%-67.3%) with follow up durations of 7 months to 3.2 years. Overall risk of bias across domains was assessed as high between included studies.</p><p><strong>Conclusions: </strong>HD remains a contentious treatment option for IC, with limited long-term results in the literature. Our study suggests longer HD times may result in improved efficacy and duration of symptom relief but in the setting of potentially increased risks of severe complications including bladder perforation. Risk of bias, observational study designs, heterogeneity, and lack direct comparisons in durations of HD limits our conclusions. ","PeriodicalId":19200,"journal":{"name":"Neurourology and Urodynamics","volume":" ","pages":"324-334"},"PeriodicalIF":1.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145636739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2026-01-18DOI: 10.1002/nau.70213
Leo Federico Stadelmeier, Elisa Lederer, Ferdinand Heimke, Marc Kidess, Nikolaos Pyrgidis, Troya Georgieva, Julian Hermans, Marina Hoffmann, Benedikt Ebner, Alexander Tamalunas, Patrick Keller, Michael Chaloupka, Ricarda Bauer, Julian Marcon, Philipp Weinhold, Christian G Stief, Yannic Volz
Objective: To assess the surgical safety, efficacy and quality of life in patients suffering from stress urinary incontinence after desobstructive surgery for benign prostatic enlargement, we analyzed data from patients treated with the Adjustable Transobturator Male System (ATOMS) at our tertiary referral center.
Methods: We retrospectively analyzed 27 patients with stress urinary incontinence (SUI) after desobstructive surgery (transurethral resection of the prostate (TUR-P): n = 17; Holmium laser enucleation of the prostate (HoLEP): n = 10) who underwent ATOMS implantation at our high-volume incontinence-surgery center between 2018 and 2024. Patients with prior prostatectomy or cancer-related surgery were excluded. Pre- and postoperative continence parameters, complications, and patient-reported outcomes were assessed using questionnaires, 24-h pad tests, and standardized instruments. The median follow-up was 32 months.
Results: Baseline demographics were comparable across groups. HoLEP patients had a significantly higher resected tissue weight (95.0 g vs. 26.0 g, p = 0.008) and required greater cushion volume (8.0 ml vs. 7.0 ml, p = 0.035). Complete continence rates were 64.7% (TUR-P) and 80.0% (HoLEP, p = 0.401). Postoperative pad test results (12.0 ml vs. 11.0 ml), complication rates, and satisfaction levels showed no significant differences. Explantation occurred in ~10% of patients, with high patient-reported satisfaction and willingness to recommend the implant across both groups.
Conclusion: ATOMS implantation is a feasible, safe, and effective treatment for SUI following both TUR-P and HoLEP. Importantly, neither the type of prior surgery nor the volume of resected prostate tissue negatively impacted outcomes. These findings support the broader application of ATOMS in patients with post-BPE SUI, including those with large prostate volumes.
目的:为了评估良性前列腺肿大去梗阻手术后压力性尿失禁患者的手术安全性、有效性和生活质量,我们分析了我们三级转诊中心使用可调男性transboturator System (ATOMS)治疗的患者的数据。方法:回顾性分析27例经尿道前列腺切除术(turp)后压力性尿失禁(SUI)患者:n = 17;钬激光前列腺去核术(HoLEP): n = 10例,于2018年至2024年间在我们的大容量失禁手术中心接受了ATOMS植入。既往有前列腺切除术或癌症相关手术的患者被排除在外。通过问卷调查、24小时尿垫试验和标准化仪器评估术前和术后尿失禁参数、并发症和患者报告的结果。中位随访时间为32个月。结果:各组间基线人口统计数据具有可比性。HoLEP患者的切除组织重量明显更高(95.0 g vs. 26.0 g, p = 0.008),需要更大的缓冲体积(8.0 ml vs. 7.0 ml, p = 0.035)。完全失禁率分别为64.7% (turp)和80.0% (HoLEP, p = 0.401)。术后尿垫试验结果(12.0 ml vs. 11.0 ml)、并发症发生率和满意度无显著差异。约10%的患者植入术成功,两组患者报告的满意度和推荐植入术的意愿都很高。结论:原子植入术是治疗turp和HoLEP合并SUI的一种可行、安全、有效的方法。重要的是,术前手术的类型和切除前列腺组织的体积都不会对结果产生负面影响。这些发现支持ATOMS在bpe后SUI患者中的更广泛应用,包括前列腺体积较大的患者。
{"title":"Adjustable TransObturator Male System (ATOMS) After Desobstructive Surgery for Benign Prostatic Hyperplasia - Does the Type of Desobstructive Surgery Make a Difference?","authors":"Leo Federico Stadelmeier, Elisa Lederer, Ferdinand Heimke, Marc Kidess, Nikolaos Pyrgidis, Troya Georgieva, Julian Hermans, Marina Hoffmann, Benedikt Ebner, Alexander Tamalunas, Patrick Keller, Michael Chaloupka, Ricarda Bauer, Julian Marcon, Philipp Weinhold, Christian G Stief, Yannic Volz","doi":"10.1002/nau.70213","DOIUrl":"10.1002/nau.70213","url":null,"abstract":"<p><strong>Objective: </strong>To assess the surgical safety, efficacy and quality of life in patients suffering from stress urinary incontinence after desobstructive surgery for benign prostatic enlargement, we analyzed data from patients treated with the Adjustable Transobturator Male System (ATOMS) at our tertiary referral center.</p><p><strong>Methods: </strong>We retrospectively analyzed 27 patients with stress urinary incontinence (SUI) after desobstructive surgery (transurethral resection of the prostate (TUR-P): n = 17; Holmium laser enucleation of the prostate (HoLEP): n = 10) who underwent ATOMS implantation at our high-volume incontinence-surgery center between 2018 and 2024. Patients with prior prostatectomy or cancer-related surgery were excluded. Pre- and postoperative continence parameters, complications, and patient-reported outcomes were assessed using questionnaires, 24-h pad tests, and standardized instruments. The median follow-up was 32 months.</p><p><strong>Results: </strong>Baseline demographics were comparable across groups. HoLEP patients had a significantly higher resected tissue weight (95.0 g vs. 26.0 g, p = 0.008) and required greater cushion volume (8.0 ml vs. 7.0 ml, p = 0.035). Complete continence rates were 64.7% (TUR-P) and 80.0% (HoLEP, p = 0.401). Postoperative pad test results (12.0 ml vs. 11.0 ml), complication rates, and satisfaction levels showed no significant differences. Explantation occurred in ~10% of patients, with high patient-reported satisfaction and willingness to recommend the implant across both groups.</p><p><strong>Conclusion: </strong>ATOMS implantation is a feasible, safe, and effective treatment for SUI following both TUR-P and HoLEP. Importantly, neither the type of prior surgery nor the volume of resected prostate tissue negatively impacted outcomes. These findings support the broader application of ATOMS in patients with post-BPE SUI, including those with large prostate volumes.</p>","PeriodicalId":19200,"journal":{"name":"Neurourology and Urodynamics","volume":" ","pages":"372-378"},"PeriodicalIF":1.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145998763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2025-10-06DOI: 10.1002/nau.70146
John Lavelle, John Hornberger
Background: Guidelines contain recommendations for monitoring and care of neurogenic lower urinary tract dysfunction (NLUTD) in patients with spinal cord injury/disorder. Evidence on the level of adherence to these recommendations is limited.
Objectives: To assess treads in proportion of patients with spinal cord injury/disorder receiving commonly recommended processes of care for NLUTD.
Methods: The cohort consisted of 49 326 veterans with supra-sacral spinal cord injury or disorder (SCI/D) within the Veterans Affairs (V.A.) healthcare system first seen from fiscal year 1999-2024. Measures included laboratories, imaging, bladder-care procedures, and whether the veteran was seen by a urologist and had cystometrography (CMG).
Results: The analysis reveals the use of recommended NLUTD monitoring processes, with 41% undergoing renal imaging, 48% having a urology encounter, and 31% receiving cystometrography. A longitudinal view shows a decline in these rates over time. However, CMG rates exhibited some increase in veterans entering the system between 2005 and 2014, indicating a slight improvement in adherence over time.
Conclusions: The study highlights gaps between current practices and recommended processes for NLUTD, which may compromise outcomes for veterans with supra-sacral SCI/D. Further research is necessary to explore the barriers to executing suggested processes and implications for outcomes of this vulnerable population.
{"title":"Adhering to Clinical Advice: The Level of Alignment of Care Processes With Global Bladder Guidelines in Veterans With Spinal Cord Injuries or Diseases.","authors":"John Lavelle, John Hornberger","doi":"10.1002/nau.70146","DOIUrl":"10.1002/nau.70146","url":null,"abstract":"<p><strong>Background: </strong>Guidelines contain recommendations for monitoring and care of neurogenic lower urinary tract dysfunction (NLUTD) in patients with spinal cord injury/disorder. Evidence on the level of adherence to these recommendations is limited.</p><p><strong>Objectives: </strong>To assess treads in proportion of patients with spinal cord injury/disorder receiving commonly recommended processes of care for NLUTD.</p><p><strong>Methods: </strong>The cohort consisted of 49 326 veterans with supra-sacral spinal cord injury or disorder (SCI/D) within the Veterans Affairs (V.A.) healthcare system first seen from fiscal year 1999-2024. Measures included laboratories, imaging, bladder-care procedures, and whether the veteran was seen by a urologist and had cystometrography (CMG).</p><p><strong>Results: </strong>The analysis reveals the use of recommended NLUTD monitoring processes, with 41% undergoing renal imaging, 48% having a urology encounter, and 31% receiving cystometrography. A longitudinal view shows a decline in these rates over time. However, CMG rates exhibited some increase in veterans entering the system between 2005 and 2014, indicating a slight improvement in adherence over time.</p><p><strong>Conclusions: </strong>The study highlights gaps between current practices and recommended processes for NLUTD, which may compromise outcomes for veterans with supra-sacral SCI/D. Further research is necessary to explore the barriers to executing suggested processes and implications for outcomes of this vulnerable population.</p>","PeriodicalId":19200,"journal":{"name":"Neurourology and Urodynamics","volume":" ","pages":"353-358"},"PeriodicalIF":1.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145239373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2025-11-12DOI: 10.1002/nau.70184
Arsalan Ikram Shah, Wenjuan Sun, Kunpeng Yang, Yong Wang
{"title":"Beyond the Scalpel: Integrating Digital Health and Artificial Intelligence to Refine Stress Urinary Incontinence Treatment Pathways.","authors":"Arsalan Ikram Shah, Wenjuan Sun, Kunpeng Yang, Yong Wang","doi":"10.1002/nau.70184","DOIUrl":"10.1002/nau.70184","url":null,"abstract":"","PeriodicalId":19200,"journal":{"name":"Neurourology and Urodynamics","volume":" ","pages":"421-422"},"PeriodicalIF":1.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145496339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2025-12-05DOI: 10.1002/nau.70194
Laira Ramos
{"title":"Does Supramaximum Force Exist? Who Can Prove It?","authors":"Laira Ramos","doi":"10.1002/nau.70194","DOIUrl":"10.1002/nau.70194","url":null,"abstract":"","PeriodicalId":19200,"journal":{"name":"Neurourology and Urodynamics","volume":" ","pages":"425-426"},"PeriodicalIF":1.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145678236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
<p><strong>Introduction: </strong>Trial without catheter (TWOC) is used to determine whether patients with acute urinary retention can achieve a catheter-free status. In clinical practice, it is common to repeat TWOC in patients who fail to void without a catheter during the first TWOC attempt. We investigated the outcomes and significance of repeat TWOC in male and female patients and aimed to identify predictors of successful outcomes of repeat TWOC based on patient backgrounds.</p><p><strong>Material and methods: </strong>Patients with acute urinary retention who underwent TWOC at a single center between 2010 and 2019 were enrolled and retrospectively analyzed. In the TWOC, the urinary catheter was removed after the instillation of warm saline (200-300 mL), and residual urine was measured after the first void. The trial was defined as unsuccessful if the patient had difficulty in voiding because of abdominal discomfort or pain. The decision to repeat the TWOC in patients who failed the first trial was made by each physician. Patients were divided into the single-trial and repeat-trial groups, and clinical factors predicting successful outcomes for each TWOC were analyzed using a multivariate logistic regression model.</p><p><strong>Results: </strong>Overall, 681 consecutive patients (577 male and 104 female) were diagnosed with acute urinary retention and underwent TWOC. Among the 577 male patients, 441 (76.4%) underwent TWOC only once (single-trial group), and 136 (23.6%) underwent TWOC twice or more (repeat-trial group). Among the 104 female patients, 84 (80.8%) and 20 (19.2%) underwent single and repeat TWOC, respectively. The overall success rate of TWOC for the single-trial and repeat-trial groups was not significantly different in either sex: 61.9% (273/441, single trial) and 55.1% (75/136, repeat trial) in male patients (p = 0.159) and 58.3% (49/84, single trial) and 55.0% (11/20, repeat trial) in female patients (p = 0.786). In the repeat-trial group, no significant and independent predictor of successful TWOC was found. In the single-trial group, low Eastern Cooperative Oncology Group performance status (odds ratio: 1.79 [1.1-2.9], p = 0.019) was identified as an independent predictor of a successful trial and absence of dementia (odds ratio: 3.82 [0.71-20.46], p = 0.118) was a possible predictor in male patients, whereas a high serum albumin level (odds ratio: 0.55 [0.27-1.15], p = 0.113) was a possible predictor of a successful trial in female patients.</p><p><strong>Conclusions: </strong>This is the first study to show the importance of repeated TWOC in male and female patients. The equivalent success rate of TWOC in the single and repeat TWOC groups for male and female patients indicates that repeat TWOC is justified as well as single TWOC, suggesting the importance of attempting repeat TWOC in patients of both sexes. This study also showed that predicting successful TWOC based on patient characteristics is difficult in repeat TWO
{"title":"Significance of Repeat Trial Without Catheter in Patients With Urinary Retention Who Failed the First Attempt at Trial Without Catheter: A 10-Year Retrospective Study.","authors":"Masato Takanashi, Hiroki Ito, Kazuhide Makiyama, Kazuki Kobayashi","doi":"10.1002/nau.70202","DOIUrl":"10.1002/nau.70202","url":null,"abstract":"<p><strong>Introduction: </strong>Trial without catheter (TWOC) is used to determine whether patients with acute urinary retention can achieve a catheter-free status. In clinical practice, it is common to repeat TWOC in patients who fail to void without a catheter during the first TWOC attempt. We investigated the outcomes and significance of repeat TWOC in male and female patients and aimed to identify predictors of successful outcomes of repeat TWOC based on patient backgrounds.</p><p><strong>Material and methods: </strong>Patients with acute urinary retention who underwent TWOC at a single center between 2010 and 2019 were enrolled and retrospectively analyzed. In the TWOC, the urinary catheter was removed after the instillation of warm saline (200-300 mL), and residual urine was measured after the first void. The trial was defined as unsuccessful if the patient had difficulty in voiding because of abdominal discomfort or pain. The decision to repeat the TWOC in patients who failed the first trial was made by each physician. Patients were divided into the single-trial and repeat-trial groups, and clinical factors predicting successful outcomes for each TWOC were analyzed using a multivariate logistic regression model.</p><p><strong>Results: </strong>Overall, 681 consecutive patients (577 male and 104 female) were diagnosed with acute urinary retention and underwent TWOC. Among the 577 male patients, 441 (76.4%) underwent TWOC only once (single-trial group), and 136 (23.6%) underwent TWOC twice or more (repeat-trial group). Among the 104 female patients, 84 (80.8%) and 20 (19.2%) underwent single and repeat TWOC, respectively. The overall success rate of TWOC for the single-trial and repeat-trial groups was not significantly different in either sex: 61.9% (273/441, single trial) and 55.1% (75/136, repeat trial) in male patients (p = 0.159) and 58.3% (49/84, single trial) and 55.0% (11/20, repeat trial) in female patients (p = 0.786). In the repeat-trial group, no significant and independent predictor of successful TWOC was found. In the single-trial group, low Eastern Cooperative Oncology Group performance status (odds ratio: 1.79 [1.1-2.9], p = 0.019) was identified as an independent predictor of a successful trial and absence of dementia (odds ratio: 3.82 [0.71-20.46], p = 0.118) was a possible predictor in male patients, whereas a high serum albumin level (odds ratio: 0.55 [0.27-1.15], p = 0.113) was a possible predictor of a successful trial in female patients.</p><p><strong>Conclusions: </strong>This is the first study to show the importance of repeated TWOC in male and female patients. The equivalent success rate of TWOC in the single and repeat TWOC groups for male and female patients indicates that repeat TWOC is justified as well as single TWOC, suggesting the importance of attempting repeat TWOC in patients of both sexes. This study also showed that predicting successful TWOC based on patient characteristics is difficult in repeat TWO","PeriodicalId":19200,"journal":{"name":"Neurourology and Urodynamics","volume":" ","pages":"390-398"},"PeriodicalIF":1.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145708684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: This study aimed to explore the association between food insecurity (FI) and lower urinary tract symptoms (LUTS) in middle-aged and older men, and to evaluate the mediating role of depression in this relationship.
Methods: Data were drawn from the National Health and Nutrition Examination Survey (NHANES) 2005-2008, including 2777 men aged 40 years and older. FI was assessed using the Household Food Security Survey Module, depression was measured by the PHQ-9 scale, and LUTS were identified via symptoms such as hesitancy, incomplete bladder emptying, incontinence, and nocturia. Weighted logistic regression and restricted cubic spline models were applied to assess associations. Mediation analysis was conducted using depression as a mediator.
Results: After full adjustment, FI was significantly associated with higher odds of incomplete bladder emptying (OR = 1.94, 95% CI: 1.11-3.36), urinary incontinence (OR = 2.11, 95% CI: 1.44-3.09), nocturia (OR = 1.59, 95% CI: 1.11-2.29), and clinical LUTS (OR = 2.49, 95% CI: 1.63-3.80). Moreover, higher PHQ-9 scores were consistently associated with increased odds of all types of LUTS, including urinary hesitancy, incomplete bladder emptying, urinary incontinence, nocturia, and clinical LUTS, in a dose-dependent manner. Mediation analysis indicated that depression partially mediated the association between FI and LUTS. Specifically, depression accounted for 12.22% of the effect of FI on urinary hesitancy, 8.90% on incomplete bladder emptying, 9.90% on urinary incontinence, 7.74% on nocturia, and 6.69% on clinical LUTS (all p < 0.05). These results demonstrate that depression plays a modest but statistically significant mediating role in the pathway linking FI to LUTS.
Conclusions: FI is significantly associated with multiple LUTS among middle-aged and older men, with depression partially mediating this relationship. Addressing both food access and mental health, particularly depression, may be critical for mitigating LUTS burden in this population.
Clinical trial registration number: Our study does not require a clinical trial registration. The survey data of our study are publicly available on the internet for data users and researchers throughout the world (https://www.cdc.gov/nchs/nhanes/?CDC_AAref_Val=https://www.cdc.gov/nchs/nhanes/index.htm).
{"title":"The Mediating Role of Depression in the Association Between Food Insecurity and Lower Urinary Tract Symptoms in Middle-Aged and Older Men: A Population-Based Study.","authors":"Meixiang Han, Cailiu Wei, Yong Fang, Yiqi Huang, Yanling Zhang, Zhongjie Qu, Fenjuan Chen","doi":"10.1002/nau.70209","DOIUrl":"10.1002/nau.70209","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to explore the association between food insecurity (FI) and lower urinary tract symptoms (LUTS) in middle-aged and older men, and to evaluate the mediating role of depression in this relationship.</p><p><strong>Methods: </strong>Data were drawn from the National Health and Nutrition Examination Survey (NHANES) 2005-2008, including 2777 men aged 40 years and older. FI was assessed using the Household Food Security Survey Module, depression was measured by the PHQ-9 scale, and LUTS were identified via symptoms such as hesitancy, incomplete bladder emptying, incontinence, and nocturia. Weighted logistic regression and restricted cubic spline models were applied to assess associations. Mediation analysis was conducted using depression as a mediator.</p><p><strong>Results: </strong>After full adjustment, FI was significantly associated with higher odds of incomplete bladder emptying (OR = 1.94, 95% CI: 1.11-3.36), urinary incontinence (OR = 2.11, 95% CI: 1.44-3.09), nocturia (OR = 1.59, 95% CI: 1.11-2.29), and clinical LUTS (OR = 2.49, 95% CI: 1.63-3.80). Moreover, higher PHQ-9 scores were consistently associated with increased odds of all types of LUTS, including urinary hesitancy, incomplete bladder emptying, urinary incontinence, nocturia, and clinical LUTS, in a dose-dependent manner. Mediation analysis indicated that depression partially mediated the association between FI and LUTS. Specifically, depression accounted for 12.22% of the effect of FI on urinary hesitancy, 8.90% on incomplete bladder emptying, 9.90% on urinary incontinence, 7.74% on nocturia, and 6.69% on clinical LUTS (all p < 0.05). These results demonstrate that depression plays a modest but statistically significant mediating role in the pathway linking FI to LUTS.</p><p><strong>Conclusions: </strong>FI is significantly associated with multiple LUTS among middle-aged and older men, with depression partially mediating this relationship. Addressing both food access and mental health, particularly depression, may be critical for mitigating LUTS burden in this population.</p><p><strong>Clinical trial registration number: </strong>Our study does not require a clinical trial registration. The survey data of our study are publicly available on the internet for data users and researchers throughout the world (https://www.cdc.gov/nchs/nhanes/?CDC_AAref_Val=https://www.cdc.gov/nchs/nhanes/index.htm).</p>","PeriodicalId":19200,"journal":{"name":"Neurourology and Urodynamics","volume":" ","pages":"399-408"},"PeriodicalIF":1.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145756244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}